Anthracyclines and taxanes are currently the most effective drugs in the treatment of metastatic breast carcinoma. The aim of this study was to determine the efficacy and toxicity of paclitaxel and doxorubicin combination in the first-line treatment of metastatic breast cancer. Forty-five women with metastatic breast cancer were recruited in the study. Median age was 49 years (range, 33-70). Treatment protocol: doxorubicin (50 mg/m2/day, 30-min infusion) followed by paclitaxel (200 mg/m2/day, 3-hr infusion) every 3 weeks. Response rates included complete response in 13 (28.9%) patients and partial response in 19 (42.2%) patients, with an overall response rate of 71%. Five (11%) patients had stable disease and 8 (18%) patients had progressive disease. At a median follow-up of 19.7 months, median time to progression for all patients was 19.9 months (95% confidence interval, 12.8 to 27 months). Median overall survival time was 28.4 months. Grade 3-4 nausea/vomiting and hematological toxicities were observed in 12 (26%) and 6 (13.3%) patients, respectively. Cardiac toxicity was observed in 2 (4.4%) patients. In this trial, paclitaxel and doxorubicin combination was demonstrated to be a favorable and active regimen in the first-line treatment of metastatic breast cancer.
LandisS.H., MurrayT., BoldenS., WingoP.A.: Cancer statistics, 1999. CA Cancer J Clin, 49: 8–31, 1999.
2.
SeidmanA., HudisC.A., FenellyD., RaptisG., BeselgaJ., NortonL.: Memorial Sloane-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. Semin Oncol, 22: 108–116, 1995.
3.
AbramsJ., VenaDa, BaltzJ., AdamsJ., MontelloM., ChristianM., OnettoN., Desmond-HellmannS., CanettaR., FriedmanM.A., ArbuckS.G.: Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center Trial. J Clin Oncol13: 2056–2065, 1995.
4.
SeidmanA., ReichmanB.S., CrownJ.P.A., YaoT.J., CurrieV., HakesT.B., HudisC.A., GilewskiT.A., BaselgaJ., ForsytheP., LeporeJ., MarksL., FainK., SouhradaM., OnettoN., ArbuckS., NortonL.: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol, 13: 1152–1159, 1995.
5.
GianniL., MunzoneE., CapriG., VillaniF., SpreaficoC., TarenziE., FulfaroF., CaraceniA., MartiniC., LaffranchiA., ValagussaP., BonadonnaG.: Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracylines. J Natl Cancer Inst, 87: 1169–1175, 1995.
6.
MartinM., LluchA., OjedaB., BarnadasA., ColomerR., MassutiB., BenitoD.: Paclitaxel plus doxorubicin in metastatic breast cancer: Preliminary analysis of cardiotoxicity. Semin Oncol, 24: 17–26, 1997.
7.
HolmesF.A., MaddenT., NewmanR.A., ValeroV., TheriaultR.L., FraschiniG., WaltersR.S., BoojerD.J., BuzdarA.U., WilleyJ., HortobagyiG.N.: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol, 14: 2713–2721, 1996.
8.
O'ShaughnessyJ.A., FishermanJ.S., CowanK.H.: Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. Semin Oncol, 21: 19–23, 1994.
9.
GianniL., ViganoL., LocatelliA., CapriG., GianiA., TarenziE., BonadonnaG.: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol, 15: 1906–1915, 1997.
10.
SledgeG.W., RobertN., SparanoJ.A., CogleighM., GoldsteinL.J., NeubergD., RowinskyE., BaughmanC., McCaskill-StevensW.: Eastern Cooperative Oncology Group study of paclitaxel and doxorubicin in advanced breast cancer. Semin Oncol, 22: 105–108, 1995.
11.
FishermanJ.S., CowanK.H., NooneM., DenicoffA., BergS., PoplackD., BalisF., VenzonD., McCabeN., GoldspielB., ChowC., OgnibeneF.P., O'ShaughnessyJ.: Phase I/II study of 72 hours infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol, 14: 774–782, 1996.
12.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment. Cancer, 47: 207–214, 1981.
13.
HolmesF.A., WaltersR.S., TheriaultR.L., FormanA.D., NewtonL.K., RaberM.N., BuzdarA.U., FryeD.K., HortobagyiG.N.: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst, 83: 1797–1805, 1991.
14.
NabholtzJ.M., GelmonK., BontenbalM., SpielmannM., CatimelG., ConteP., KlaassenU., NamerM., BonnettereJ., FumoleauP., WinogradB.: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol, 14: 1858–1867, 1996.
15.
GianniL., MunzoneE., CapriG., FulfaroF., TarenziE., VillaniF., SpreaficoC., LaffranchiA., CaraceniA., MartiniC., StefanelliM., ValagussaP., BonadonnaG.: Paclitaxel by a 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol, 13: 2688–2699, 1995.
16.
GehlJ., BoesgaardM., PaaskeT., Vittrup JensenB., DombernowskyP.: Combined doxorubicin and paclitaxel in advanced breast cancer, effective and cardiotoxic. Ann Oncol, 7: 687–693, 1996.
17.
JassemJ., PienkowskiT., PluzanskaA., JelicS., GorbunovaV., Mrsic-KrimpoticZ., BerzinsJ., NagykalnaiT., WiglerN., RenardJ., MunierS., WeilC.: Doxorubicin an paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III multicenter trial. J Clin Oncol, 19: 1707–1715, 2001.
18.
GianniL.: Future directions of paclitaxel-based therapy of breast cancer. Semin Oncol, 24: 91–96, 1997.
19.
BiganzoliL., CuferT., BruningP., ColemanR., CalvertH., GamucciT., TwelvesC., Donato di PaolaE., DuchateauL., YagueC., EpelbaumR., PiccartM.: Doxorubicin (A)/Taxol (T) versus doxorubicin/cyclophosphamide (C) as first line chemotherapy in metastatic breast cancer (MBC): a phase III study. Proc Am Soc Clin Oncol, 19: 73 (abst), 2000.
20.
SledgeG.W., NeubergD., IngleJ., MartinoS., WoodW.: Phase III trial of doxorubicin vs paclitaxel vs doxorubicin plus paclitaxel as first line therapy for metastatic breast cancer: an Intergroup Triat. Proc Am Soc Clin Oncol, 15: 1 (abst), 1997.
21.
LuckH.J., ThomssenC., UntchM., KuhnW., EidtmannH., BoisA.D., OlbrichtS., MoebusV., SteinfeldD., BauknechtT., SchroederW., JackischC.: Multicentric phase II study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the AGO breast cancer group. Proc Am Soc Clin Oncol, 19: 73 (abst), 2000.
